An anonymous director reports

RESVERLOGIX CORP. ANNOUNCES FILING OF ANNUAL FILINGS AND REVOCATION OF MCTO

Resverlogix Corp. has obtained the revocation, effective April 15, 2026, of a management cease trade order (MCTO) issued by the Alberta Securities Commission (the ASC) on April 1, 2026, at the request of the company.

The company filed its audited financial statements, management's discussion and analysis, certifications of annual filings, and annual information form for the year ended Dec. 31, 2025, on April 10, 2026.

The MCTO applied only to the company's chief executive officer and chief financial officer, and did not restrict trading by the general investing public.

The company confirms it is current with its disclosure obligations and anticipates complying with upcoming filing deadlines.

About Resverlogix Corp.

Founded in 2001, Resverlogix is a Calgary-based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.

Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. The company aims to improve patients' lives by restoring biological functions -- altered by serious illnesses such as cardiovascular disease -- back to a healthier state.

The company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities and post COVID-19 conditions.

We seek Safe Harbor.